Uses of JAK Inhibitors in the Management of Sepsis and Comorbidities

Abstract

Disclosed are methods of treating, preventing, or reversing sepsis and comorbidities comprising administering an effective amount of a Janus kinases (JAK) inhibitor such as baricitinib to a patient in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of or diagnosed with sepsis-associated organ failure, sepsis associated encephalopathy, sepsis associated acute kidney injury, sepsis induced cardiac dysfunction, sepsis induced acute respiratory distress, and/or hepato-splanchnic dysfunction.

Dependencies are inferred from the claim text.